Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Outlook Therapeutics (OTLK) over the last 8 years, with Q4 2025 value amounting to $7.6 million.

  • Outlook Therapeutics' Other Non-Current Liabilities fell 5984.17% to $7.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $7.6 million, marking a year-over-year decrease of 5984.17%. This contributed to the annual value of $4.8 million for FY2025, which is N/A changed from last year.
  • As of Q4 2025, Outlook Therapeutics' Other Non-Current Liabilities stood at $7.6 million, which was down 5984.17% from $4.8 million recorded in Q3 2025.
  • Over the past 5 years, Outlook Therapeutics' Other Non-Current Liabilities peaked at $18.8 million during Q4 2024, and registered a low of $4.8 million during Q3 2025.